Pablo J Cagnoni's Net Worth
$15.6 Million
Who is Pablo J Cagnoni?
Pablo J Cagnoni has an estimated net worth of $15.6 Million. This is based on reported shares across multiple companies, which include Fusion Pharmaceuticals Inc., CRISPR Therapeutics AG, Rubius Therapeutics, Inc., TURMERIC ACQUISITION CORP., INCYTE CORP, ALLOS THERAPEUTICS INC, ONYX PHARMACEUTICALS INC, and OSI PHARMACEUTICALS INC.
SEC CIK
Pablo J Cagnoni's CIK is 0001205703
Past Insider Trading and Trends
2018 was Pablo J Cagnoni's most active year for acquiring shares with 7 total transactions. Pablo J Cagnoni's most active month to acquire stocks was the month of May. 2004 was Pablo J Cagnoni's most active year for disposing of shares, totalling 13 transactions. Pablo J Cagnoni's most active month to dispose stocks was the month of July. 2007 saw Pablo J Cagnoni paying a total of $1,851,000.00 for 375,000 shares, this is the most they've acquired in one year. In 2013 Pablo J Cagnoni cashed out on 50,287 shares for a total of $2,032,125.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Fusion Pharmaceuticals Inc. (FUSN) Snapshot price: $11.89
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CRISPR Therapeutics AG (CRSP) Snapshot price: $66.91
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$33.80 | -$423,075.00 |
0
|
Scheduled
|
Nov 19
| ||
Form 4
|
—
|
0
|
$30.30 | -$370,575.00 |
0
|
Scheduled
|
Nov 12
| ||
Form 4
|
—
|
0
|
$28.80 | -$348,075.00 |
0
|
Scheduled
|
Oct 30
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 11
| |||
Form 4
|
—
|
0
|
$33.80 | -$423,075.00 |
0
|
Scheduled
|
Jul 3 - Jul 5
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Rubius Therapeutics, Inc. (RUBY) Snapshot price: $0.057
CEO and President
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -11.34% | -8.45K |
$0.25 | -$2,112.00 | 66.08K |
Feb 1
| |||
Form 4
| +109.83% | 39.01K |
$0.24 | -$1,744.84 | 74.53K |
Jan 29 - Jan 31
| |||
Form 4
| +69.14% | 14.52K |
$6.57 | -$44,236.29 | 35.52K |
Jan 29 - Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 29
| |||
Form 4
|
∞
| 21K |
$4.70 | $98,693.70 | 21K |
Apr 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 31
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
TURMERIC ACQUISITION CORP. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
INCYTE CORP (INCY) Snapshot price: $59.27
President, R&D
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 18
| |||
Form 4
| +5.02% | 9.67K |
—
|
—
| 202.07K |
Jul 14
| |||
Form 4/A
|
∞
| 192.4K |
—
|
—
| 192.4K |
Jun 5
| |||
Form 4
|
∞
| 179.61K |
—
|
—
| 179.61K |
Jun 5
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||